Aveanna Healthcare Holdings stock jumped about 9% to US$12.32 into the weekend, capping a strong run over the past month. That move came as the company posted Q2 revenue of US$670.5m and adjusted earnings before interest, tax, depreciation and amortisation of US$95.4m, and lifted full year guidance above US$2.68b of revenue and more than US$365m of adjusted EBITDA.

For a home based care provider that lives and dies on contract rates, labour costs and leverage, the headline is simple: the guidance upgrade is doing the talking and the stock is listening.

Is Aveanna Healthcare Holdings really a bargain at a P/E of about 9.8x compared with peers on more than 40x, or is the low multiple a warning sign about future earnings pressure? See how the market price compares with fundamentals in our valuation analysis for Aveanna Healthcare Holdings

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$670.5m vs. US$589.6m (up about 13.7%)
• Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): US$40.3m vs. US$27.0m (up about 49.1%)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.185 vs. US$0.134 (up about 37.6%)
• Trailing 12 Month Net Profit Margin (Q2 2026 vs prior year TTM): 10.6% vs. 1.0% (margin improved very significantly)

Prefer clear visuals instead of another wall of earnings tables and footnotes? See Aveanna Healthcare Holdings' full financial picture, with a focus on its valuation, in an easy visual format in our company report for Aveanna Healthcare Holdings.

Aveanna bull case hits key operational markers

Bulls argue Aveanna Healthcare can turn demand for home based care and a richer preferred payer mix into steadier margins and cash flow. Q2 results largely back that up. Revenue grew 13.7% while adjusted EBITDA grew 8%, which shows growth is coming with some cost pressure but not breaking the model. Preferred payer penetration in Private Duty Services is about 64% and Home Health has 50 preferred agreements with episodic mix around 81%. That lines up with the claim that Aveanna is shifting towards better quality reimbursement. Seven state PDS rate wins and the California pediatric investment earmarked for 2027 support the story that advocacy is starting to pay off. Higher full year revenue and EBITDA guidance, along with around US$75.4m of free cash flow year to date, indicates the business is funding growth and M&A without stretching liquidity.

Bear case focuses on margin strain and policy risk

The bear story centers on reimbursement concentration, labor cost pressure and execution risk offsetting Aveanna Healthcare’s growth. Q2 margins give that concern some backing. Adjusted EBITDA grew slower than revenue and PDS gross margin of about 28.9% suggests limited room for error as wage pass through starts ahead of the 2027 California rate. Management is leaning into higher pay now to improve fill rates, which could squeeze spreads if any rate implementation slips. The heavy Medicaid and government exposure still matters despite recent state wins, since timing and exact rate details are not yet locked in. Variable rate debt of about US$1.48b keeps interest sensitivity in focus even with hedges and the 75 bps term loan repricing. The Family First acquisition is integrating smoothly, but leverage temporarily ticked up, so the sub 3x target by 2027 still needs proof over multiple quarters.

Reveal where Aveanna Healthcare Holdings' calm-looking share price might hide the biggest disagreement in the street models, and see at what point the multi year forecasts start to diverge. Access the full revenue, margin and EPS analyst estimates for Aveanna Healthcare Holdings.

Take Control Of Your Next Move

If Aveanna Healthcare Holdings’ guidance upgrade and low P/E relative to peers has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot an entry point that fits your plan. Once you are invested, keep a clear view of your positions and get focused alerts that cut through noise with the Portfolio Command Center. For a longer term view, use the Community to see how other investors are thinking about risks, opportunities and changing assumptions. By surfacing potential catalysts and pressure points early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Aveanna Healthcare Holdings?

Fresh stock ideas can move from under the radar to flying high fast. Spot potential breakout candidates before the crowd while the data still matters. Act now.

• Ride potential momentum in cash generative companies before they are widely talked about by scanning a curated 50 high quality undervalued stocks that still look overlooked by many investors.
• Target income opportunities that may help steady your portfolio by reviewing a focused list of 10 dividend fortresses that have kept payouts front and center.
• Get ahead of the next wave in automation by checking a tight group of 37 robotics and automation stocks that could benefit if adoption keeps building across industries.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.